Every 10-Q that BioSig Technologies, Inc. (BSGM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BSGM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSGM filings page.
Streamex Corp. reported a quarter with no revenue and a net loss attributable to common shareholders of $46.7 million, driven mainly by $34.3 million of general and administrative expenses and heavy non‑cash interest on prior debt.
The company reshaped its balance sheet by eliminating $50 million of secured convertible debentures through a mix of $38.9 million cash repayment and conversion of $15 million of principal into 3.75 million common shares. A January 2026 underwritten equity offering provided $37.2 million of net proceeds.
As of March 31 2026, Streamex held $6.9 million of cash, working capital of $42.6 million, total assets of $173.3 million, and no debt. The balance sheet is dominated by goodwill and intangibles from the Streamex Exchange acquisition and $15.2 million of gold held in a Cayman VIE to back GLDY Tokens. Management expects continued operating losses but believes current liquidity supports at least 12 months of operations.
Streamex Corp. (Nasdaq: STEX) filed its Q3 report, reflecting a transformative acquisition and a materially weaker balance sheet. Total assets rose to $130.5 million, driven by $69.9 million of goodwill and $45.4 million of intangible assets from the May 28 acquisition of Streamex Exchange. Cash increased to $11.0 million, but the company posted no revenue for Q3 and the year-to-date period.
The quarter showed a net loss of $15.6 million (Q3) and $38.8 million (nine months), as operating expenses and a $10.2 million loss from remeasuring a derivative liability weighed on results. Current liabilities surged to $125.6 million, including a $115.7 million derivative liability tied to exchangeable shares issued in the acquisition, leading to a stockholders’ deficit of $(6.9) million. Management disclosed substantial doubt about continuing as a going concern due to a $111 million working capital deficit and operating cash use of $7.4 million.
As a subsequent event, on November 4, 2025 shareholders approved lifting the 19.99% cap on conversions, allowing exchangeable shares to convert into common stock and triggering reclassification of the derivative liability to equity.
BioSig Technologies (BSGM) reported a substantial net loss of $20,368 and $23,169 for the three- and six-month periods presented, respectively, and a working capital deficit of $110 million, which management states raises substantial doubt about the company’s ability to continue as a going concern. The balance sheet includes a $105,498 derivative/Exchangeable Shares liability that remains classified as a liability because shareholder approval and other contingencies have not been resolved. The company completed the acquisition of Streamex, recording $57.8 million of goodwill and material intangible assets (developed technology and legal/compliance framework). Financing and equity activity during the period included multiple stock offerings, an at-the-market program raising net proceeds of about $3.88 million, and extensive issuance of common stock, RSUs, warrants, and preferred cumulative dividends recorded.